Obesity & OverweightPhase 1NCT07324850
A Study of SGB-7342 in Subjects With Obesity or Overweight
A Phase 1 study testing SGB-7342 in people with Obesity & Overweight, run by Suzhou Sanegene Bio Inc..
Trial summary
The purpose of this study is to evaluate the safety and tolerability of subcutaneously administered SGB-7342 in adult subjects with obesity and overweight. Read more about this study
- Who is it for?
- Ages 18 to 55 years
- Conditions the study is for
- Obesity & Overweight
- What is being tested?
- SGB-7342
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 45 participants
- Where
- No sites listed yet
- Study dates
- 12 Jan 2026to 14 Apr 2027
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Body Mass Index (BMI) within the range of 26.0 to 35.0 kg/m²
- Have a stable body weight within 3 months
- Participants must agree to use adequate contraception from signing the informed consent until 6 months after completion of the follow-up visit.
- Willing to comply with the protocol required visit schedule and visit requirements and provide written informed consent.
Who cannot join
- A history of or a current surgical or medical condition that, in the opinion of the Investigator, may put the subject at significant risk (according to Investigator's judgment) or interfere with the subject's participation in the clinical study.
- Use of GLP-1R agonists for any indication within 6 months prior to administering the investigational drug.
- Use of non-GLP1R medications for weight loss within 3 months prior to administering the investigational drug.
- Alanine aminotransferase (ALT), total bilirubin (TBIL), aspartate aminotransferase (AST)> 1.5 × ULN, and deemed clinically significant by the Investigators
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-7342 in Subjects With Obesity or Overweight
The purpose of this study is to evaluate the safety and tolerability of subcutaneously administered SGB-7342 in adult subjects with obesity and overweight.
- Conditions
- Obesity & Overweight
- Being tested
- SGB-7342, SGB-7342-Matching placebo
- Medical subject headings
- Obesity, Overweight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SGB-7342Drug
SC injection, single dose
SGB-7342-Matching placeboDrug
Normal saline (0.9% NaCl) in a matching volume, SC injection, single dose
| Study group | Role | What they receive |
|---|---|---|
| SGB-7342 | Experimental | Not described Receives: Drug: SGB-7342 |
| SGB-7342-Matching placebo | Placebo comparator | Not described Receives: Drug: SGB-7342-Matching placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants with Adverse Events (AEs)
Measured: up to approximately 6 months
Secondary outcomes (3)
Maximum Observed Plasma Concentration (Cmax)
Measured: up to approximately 3 days
Area Under the Concentration-time Curve (AUC)
Measured: up to 3 days
Weight change from baseline
Measured: up to approximately 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jan 2026
- Study start12 Jan 2026 (estimated)
- Primary completion28 Oct 2026 (estimated)
- Study completion14 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obesity & OverweightStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 45 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Suzhou Sanegene Bio Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07324850
- Sponsor's protocol ID
- SGB-7342-001
- Status last verified
- Jan 2026
- First submitted
- 23 Dec 2025
- Last updated
- 9 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-7342 in Subjects With Obesity or Overweight
- ClinicalTrials.gov ID
- NCT07324850
- Acronym / sponsor ID
- SGB-7342-001
- Conditions
- Obesity & Overweight
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 45 participants (estimated)
- Lead sponsor
- Suzhou Sanegene Bio Inc.Industry (pharma, biotech, devices)
- Study start
- 12 Jan 2026 (estimated)
- Primary completion
- 28 Oct 2026 (estimated)
- Study completion
- 14 Apr 2027 (estimated)
- First posted
- 8 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the safety and tolerability of subcutaneously administered SGB-7342 in adult subjects with obesity and overweight.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| SGB-7342 | Experimental | Drug: SGB-7342 |
| SGB-7342-Matching placebo | Placebo comparator | Drug: SGB-7342-Matching placebo |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Body Mass Index (BMI) within the range of 26.0 to 35.0 kg/m²
- Have a stable body weight within 3 months
- Participants must agree to use adequate contraception from signing the informed consent until 6 months after completion of the follow-up visit.
- Willing to comply with the protocol required visit schedule and visit requirements and provide written informed consent.
Key exclusion criteria (4 listed)
- A history of or a current surgical or medical condition that, in the opinion of the Investigator, may put the subject at significant risk (according to Investigator's judgment) or interfere with the subject's participation in the clinical study.
- Use of GLP-1R agonists for any indication within 6 months prior to administering the investigational drug.
- Use of non-GLP1R medications for weight loss within 3 months prior to administering the investigational drug.
- Alanine aminotransferase (ALT), total bilirubin (TBIL), aspartate aminotransferase (AST)> 1.5 × ULN, and deemed clinically significant by the Investigators
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SGB-7342SC injection, single dose | Drug | SGB-7342 |
| SGB-7342-Matching placeboNormal saline (0.9% NaCl) in a matching volume, SC injection, single dose | Drug | SGB-7342-Matching placebo |
Primary outcome
Number of Participants with Adverse Events (AEs)
Time frame: up to approximately 6 months
3 secondary outcomes
Maximum Observed Plasma Concentration (Cmax)
Time frame: up to approximately 3 days
Area Under the Concentration-time Curve (AUC)
Time frame: up to 3 days
Weight change from baseline
Time frame: up to approximately 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jan 2026.
Related trials for Obesity & Overweight
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing SGB-7342 in people with Obesity & Overweight, run by Suzhou Sanegene Bio Inc..
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 9 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact SGB.clinical (+086 021-60209828, SGB.clinical@sanegenebio.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants with Adverse Events (AEs) (time frame: up to approximately 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jan 2026.